Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Tuberculosis is a chronic wasting infectious disease caused by Mycobacterium tuberculosis. The drugs used to treat this disease are anti-tuberculosis drugs.
Market Analysis and Insights: Global Anti-Tuberculosis Drug Market
Due to the COVID-19 pandemic, the global Anti-Tuberculosis Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, First-Line Anti-Tuberculosis Drugs accounting for % of the Anti-Tuberculosis Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Anti-Tuberculosis Drug market size is valued at US$ million in 2021, while the US and Europe Anti-Tuberculosis Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Anti-Tuberculosis Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Anti-Tuberculosis Drug include Lupin, Otsuka, Sanofi, Prizer, Abbott and NOVARTIS, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Anti-Tuberculosis Drug Scope and Segment
Anti-Tuberculosis Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Anti-Tuberculosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
First-Line Anti-Tuberculosis Drugs
Second-Line Anti-Tuberculosis Drugs
Segment by Application
Hospital
Clinic
Others
By Company
Lupin
Otsuka
Sanofi
Prizer
Abbott
NOVARTIS
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Market Analysis and Insights: Global Anti-Tuberculosis Drug Market
Due to the COVID-19 pandemic, the global Anti-Tuberculosis Drug market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, First-Line Anti-Tuberculosis Drugs accounting for % of the Anti-Tuberculosis Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Anti-Tuberculosis Drug market size is valued at US$ million in 2021, while the US and Europe Anti-Tuberculosis Drug are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Anti-Tuberculosis Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Anti-Tuberculosis Drug include Lupin, Otsuka, Sanofi, Prizer, Abbott and NOVARTIS, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Anti-Tuberculosis Drug Scope and Segment
Anti-Tuberculosis Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Anti-Tuberculosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
First-Line Anti-Tuberculosis Drugs
Second-Line Anti-Tuberculosis Drugs
Segment by Application
Hospital
Clinic
Others
By Company
Lupin
Otsuka
Sanofi
Prizer
Abbott
NOVARTIS
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
